NASDAQ:INCY - Incyte Stock Price, Forecast & News

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte Co. (NASDAQ:INCY) posted its quarterly earnings results on Tuesday, October, 29th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.27. The biopharmaceutical company earned $551.58 million during the quarter, compared to analyst estimates of $534.73 million. Incyte had a return on equity of 20.07% and a net margin of 19.21%. The business's revenue was up 22.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.41 earnings per share. View Incyte's Earnings History.

Incyte is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Incyte.

23 brokerages have issued twelve-month target prices for Incyte's shares. Their forecasts range from $65.00 to $121.00. On average, they expect Incyte's stock price to reach $92.36 in the next year. This suggests a possible upside of 14.7% from the stock's current price. View Analyst Price Targets for Incyte.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Incyte.

Headlines about INCY stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Incyte earned a daily sentiment score of -2.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Incyte.

Incyte saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 3,950,000 shares, a decrease of 14.5% from the December 15th total of 4,620,000 shares. Based on an average trading volume of 1,320,000 shares, the short-interest ratio is currently 3.0 days. Currently, 1.9% of the shares of the stock are short sold. View Incyte's Current Options Chain.

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Array Biopharma (ARRY), Celgene (CELG) and Micron Technology (MU).

Incyte's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Manning & Napier Group LLC (0.23%), Country Trust Bank (0.18%), Assenagon Asset Management S.A. (0.06%), Rhenman & Partners Asset Management AB (0.03%), Commerzbank Aktiengesellschaft FI (0.02%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Incyte stock include Barry P Flannelly, David W Gryska, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing. View Institutional Ownership Trends for Incyte.

INCY stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, First Hawaiian Bank, State of Alaska Department of Revenue, Tributary Capital Management LLC, Steward Partners Investment Advisory LLC, IFM Investors Pty Ltd and Raymond James Trust N.A.. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing. View Insider Buying and Selling for Incyte.

INCY stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Rhenman & Partners Asset Management AB, Commerzbank Aktiengesellschaft FI, Country Trust Bank, Nisa Investment Advisors LLC, SevenBridge Financial Group LLC, Alpine Global Management LLC and Diversified Trust Co. Company insiders that have bought Incyte stock in the last two years include Herve Hoppenot and Jean Jacques Bienaime. View Insider Buying and Selling for Incyte.

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INCY stock can currently be purchased for approximately $80.50.

Incyte has a market capitalization of $17.34 billion and generates $1.88 billion in revenue each year. The biopharmaceutical company earns $109.49 million in net income (profit) each year or $0.82 on an earnings per share basis. Incyte employs 1,367 workers across the globe.View Additional Information About Incyte.

The official website for Incyte is http://www.incyte.com/.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]